American Academy of Ophthalmology: New Ovarian Cancer Drug Can Affect the Eyes, Suggests First Real-World Study
October 18, 2024
October 18, 2024
SAN FRANCISCO, California, Oct. 18 (TNSres) -- The American Academy of Ophthalmology issued the following news release:
* * *
Most patients on mirvetuximab soravtansine experience corneal toxicity, vigilant ophthalmology follow up recommended
* * *
CHICAGO, Ill. -- When the U.S. Food and Drug Administration granted accelerated approval for the ovarian cancer drug mirvetuximab soravtansine (Elahere) in 2022, it came with a label warning that it . . .
* * *
Most patients on mirvetuximab soravtansine experience corneal toxicity, vigilant ophthalmology follow up recommended
* * *
CHICAGO, Ill. -- When the U.S. Food and Drug Administration granted accelerated approval for the ovarian cancer drug mirvetuximab soravtansine (Elahere) in 2022, it came with a label warning that it . . .